India's new drug approval process waiver raises concerns about patient safety, research, and healthcare implications, experts ...

In a significant breakthrough for those suffering from chronic hand eczema, a widespread skin condition resistant to existing ...

Clinical trials in 2025 will be beset by rising costs and uncertain regulations while also benefiting from new technologies ...

Some 90% of investigational drugs fail—and success rates are even more dire in the neuro space. Here, BioSpace looks at five ...

A patient advocate discusses the difficulties of finding and participating in clinical trials for MPNs, and the impact on ...

China: A new randomized clinical trial has demonstrated that QX004N, a humanized anti-IL-23 monoclonal antibody, offers ...

Phase I clinical trial of a drug was successfully completed, with promise to treat Alzheimer's and other neurodegenerative diseases. The compound, named VU319, is the first end-to-end drug discovery ...

Viracta Therapeutics shares were trading lower after it said it will end an ongoing trial of Nana-val and its board has initiated a process to explore strategic options. The strategic options being ...

The clinical trial will assess CMND-100’s ability to reduce alcohol cravings and consumption among individuals with moderate to severe AUD. The study is designed to gather critical data supporting the ...

The Eclipse Trial is researching an investigational vaccine to protect against Epstein-Barr virus (EBV) and infectious ...

About 87.5% of patients treated with the drug were alive after six years, compared to 83.2% who received a placebo.

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers ...